AGS-1C4D4 in Patients With Advanced Hormone Refractory Prostate Cancer

Completed · Phase 1

Conditions studied: Prostate Cancer

In brief

The present study will investigate the safety, tolerability and spectrum of side effects of AGS-1C4D4. As such, this study will characterize the dose limiting toxicities (DLT) and potentially the maximum tolerated dose (MTD) of AGS-1C4D4 in patients with advanced HRPC.

Key facts

Study ID

NCT00519233

Run by

Astellas Pharma Inc

People needed

13

Starts

2007-09-01

Expected to finish

2009-09-01

Last updated by the study team

2014-05-02

Who can join

Age: 18 and older. Sex: male. Healthy volunteers: not accepted.

You may qualify if…

• Patient has hormone-refractory metastatic prostate cancer

You may not qualify if…

• Patient has had chemotherapy, radiotherapy, or biological therapy within the past 4 weeks or has not recovered from side effects
• Patient is currently participating or has participated in an investigational study within the past 30 days
• Patient has illness or circumstance that could limit compliance with the study requirements
• Patient uses illicit drugs or had a recent history of drug or alcohol abuse within the last year
• Patient has Hepatitis B or C

Where it is running

• Study site — Baltimore, Maryland, United States
• Study site — New York, New York, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.